Complaints To CDER Down, But Lorcaserin Weighs Heavily At Ombudsman's Office

Investors in Arena Pharmaceuticals and others angered by an advisory panel vote last September against approving the company's obesity drug Lorqess (lorcaserin) sent 467 complaints to the CDER Ombudsman's Office.